Document Detail


Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.
MedLine Citation:
PMID:  10540047     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Heparin given intravenously has shown beneficial effects in the treatment of refractory ulcerative colitis in open trials. Low molecular weight heparin (LMWH) offers advantages in the method of administration but have not been evaluated in inflammatory bowel disease conditions. AIM: To assess the tolerability and safety of subcutaneous self-administered LMWH in outpatients with refractory ulcerative colitis and to evaluate any potential adjuvant therapeutic effect. PATIENTS AND METHODS: Twelve patients with mild to moderately active ulcerative colitis were included in the trial. The patients had either responded poorly to treatment with conventional therapy, including oral and/or rectal glucocorticosteroids, or had experienced a rapid relapse during or shortly after GCS therapy. Dalteparin sodium 5000 units s.c. injection was administered twice daily for 12 weeks. Patients were monitored for possible adverse events and changes in clinical symptoms, and endoscopic and histological scores were analysed. Leucocyte scanning was performed at inclusion and at the end of the study. RESULTS: Tolerability and compliance were excellent and no serious adverse events occurred. Eleven patients improved symptomatically and six (50%) attained complete remission after 12 weeks of treatment. Endoscopic, scintigraphic and histological scores were found to be significantly improved. CONCLUSION: Self-administered LMWH given s.c. may be a safe adjuvant therapy for patients with active, glucocorticosteroids-refractory ulcerative colitis. A controlled trial should be undertaken to confirm the positive effects found in this study.
Authors:
L Törkvist; H Thorlacius; U Sjöqvist; L Bohman; A Lapidus; L Flood; B Agren; J Raud; R Löfberg
Related Documents :
11700817 - Improving the treatment of leg ulcers.
7137137 - Gastric epithelial dysplasia in relapsing and nonrelapsing gastric ulcer.
17903157 - Endovenous laser treatment for varicose veins in patients with active ulcers: measureme...
16869197 - Use of ulcer size and initial responses to treatment to predict the healing time of leg...
9583547 - Pleural bupivacaine placement for optimal postthoracotomy pulmonary function: a prospec...
19182607 - Activated protein c improves ischemic flap survival and modulates proangiogenic and ant...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  13     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  1999 Oct 
Date Detail:
Created Date:  1999-11-18     Completed Date:  1999-11-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1323-8     Citation Subset:  IM    
Affiliation:
Department of Surgical and Medical Gastroenterology, Karolinska Institutet at Huddinge University Hospital, Sweden. leif.torkvist@karo.ki.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anticoagulants / adverse effects,  therapeutic use*
Chemotherapy, Adjuvant
Colitis, Ulcerative / drug therapy*,  radionuclide imaging
Female
Glucocorticoids / adverse effects,  therapeutic use
Heparin, Low-Molecular-Weight / adverse effects,  therapeutic use*
Humans
Male
Middle Aged
Radiopharmaceuticals / diagnostic use
Technetium Tc 99m Exametazime / diagnostic use
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Glucocorticoids; 0/Heparin, Low-Molecular-Weight; 0/Radiopharmaceuticals; 100504-35-6/Technetium Tc 99m Exametazime

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Helicobacter pylori treatment instead of maintenance therapy for peptic ulcer disease: the effective...
Next Document:  Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic...